ArticleCancer letters2014
Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.
Article in Cancer letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Physiological elasticity and topography modulateiScience · 2026Article
- Comprehensive Profiling Reveals Sialyl-Tn Upregulation and Prognostic Value in Prostate Cancer.Pathology international · 2026Article
- Preclinical screening models in anticancer drug development: strengths, limitations, and translational challenges.Frontiers in pharmacology · 2026Review
- Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- AZGP1 deficiency promotes angiogenesis in prostate cancer.Journal of translational medicine · 2024Article
- Prostate cancer research: tools, cell types, and molecular targets.Frontiers in oncology · 2024Review
- SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.Cell reports. Medicine · 2022Article
- High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids.SLAS discovery : advancing life sciences R & D · 2021Article
- Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.Nature communications · 2021Article
- Rosuvastatin inhibit spheroid formation and epithelial-mesenchymal transition (EMT) in prostate cancer PC-3 cell line.Molecular biology reports · 2020Article
- PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery.Journal of the Endocrine Society · 2020Review
- The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.EMBO molecular medicine · 2019Article
- Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models.Cold Spring Harbor perspectives in medicine · 2018Review
- Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.Journal of translational medicine · 2017Article
- Progression inference for somatic mutations in cancer.Heliyon · 2017Article
- Patient-Derived Prostate Cancer: from Basic Science to the Clinic.Hormones & cancer · 2016Review
- Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.Clinical & experimental metastasis · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
LuCaP serially transplantable xenografts are valuable preclinical models of locally advanced or metastatic prostate cancer. For the first time, we recently succeeded in establishing and serially passaging spheroid cultures of several LuCaP xenografts. Here, we characterized in depth the molecular and cellular phenotype of LuCaP 147 cultures and found faithful retention of the characteristics of the original xenograft, including immunophenotype, genetic fidelity, gene expression profile and responsiveness to androgen. Furthermore, we demonstrated capabilities for high-throughput drug screening and that anti-cancer agents induced cell cycle arrest and apoptosis in spheroid cultures. Finally, we showed that cells formed tumors when re-introduced into mice, providing an authentic in vitro-in vivo preclinical model of a subtype of prostate cancer with a hypermutator phenotype and an SPOP mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.